Urogen Pharma Q3 EPS Forecast Decreased by HC Wainwright

Urogen Pharma (NASDAQ:URGN) – Research analysts at HC Wainwright decreased their Q3 2025 earnings per share estimates for shares of Urogen Pharma in a research report issued on Monday, August 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.73) per share for the quarter, down from their previous estimate of ($0.69). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($1.18) EPS.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%.

Several other brokerages have also issued reports on URGN. Scotiabank reaffirmed an “outperform” rating on shares of Urogen Pharma in a research note on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the company a “neutral” rating in a research note on Friday, June 13th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Urogen Pharma in a report on Tuesday, August 5th. Guggenheim reiterated a “buy” rating and set a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a “buy” rating in a research report on Friday, June 13th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Urogen Pharma presently has a consensus rating of “Buy” and a consensus price target of $31.43.

Urogen Pharma Trading Down 0.1%

Shares of NASDAQ:URGN opened at $20.08 on Thursday. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $21.01. The stock has a market capitalization of $928.90 million, a P/E ratio of -6.05 and a beta of 1.12. The business has a 50-day moving average price of $15.21 and a two-hundred day moving average price of $11.59.

Hedge Funds Weigh In On Urogen Pharma

Several institutional investors and hedge funds have recently modified their holdings of URGN. CWM LLC raised its holdings in Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock worth $58,000 after buying an additional 5,140 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Urogen Pharma during the fourth quarter worth $67,000. GAMMA Investing LLC lifted its position in Urogen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after acquiring an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Urogen Pharma in the 4th quarter worth $101,000. Finally, ProShare Advisors LLC acquired a new position in Urogen Pharma in the 4th quarter worth $137,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,522 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the transaction, the general counsel directly owned 41,492 shares of the company’s stock, valued at approximately $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider owned 148,229 shares of the company’s stock, valued at $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,833 shares of company stock valued at $457,467 in the last three months. 4.70% of the stock is owned by company insiders.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.